| Qualifications and capacity: |
Professors A. Noël and J.-M. Foidart are co-coordinating the Laboratory of Tumour and
Development Biology in Liège, composed of 50 persons (16 Post-doc, 2 PhD, 19 PhD students,
13 technicians).
Agnès Noël (PhD) is Professor of Cell and Molecular Biology of the University of Liège.
She has gained expertise in tumour biology and contributed to demonstrate the importance
of proteases, their
inhibitors and host-tumour interactions in
cancer progression.
Her group has developed in vivo and in vitro models which are useful for studying
different steps of metastatic dissemination, and recently it has set up a novel model
of ex vivo lymphangiogenesis, the lymphatic ring assay
(access).
Jean-Michel Foidart (MD, PhD) is Chairman of the Department of Obstetrics and Gynaecology
in the Liege University Hospital (CHU). He has a strong background in the biochemistry of
extracellular matrix components, on proteases
and their inhibitors. He is contributing in the
setting up of a tumour bank in the
GIGA-Cancer.
They are members of the GIGA-Cancer
composed of 283 researchers working on genomic and proteomic.
Erik Maquoi (PhD) is a Research Associate of the National Fund for Scientific Research (FNRS).
He is an expert in biochemistry of MMPs, proteomic and genomic analysis.
Christine Gilles (PhD) is a Research Associate of the FNRS and expert in cell migration and
in vivo cell tracking with the Xenogen system.
Olivier Peulen (PhD) is a Professor Assistant in Biology. He is the Project co-Manager of the
Microenvimet project.
Mélanie Mestdagt (PhD) is Senior Researcher in Biomedical Sciences.
She is the Project co-Manager of the Microenvimet project.
|
|
Most relevant publications:
|
The plasminogen activator inhibitor PAI-1 controls tumour vascularization by interaction with proteases, not vitronectin: implications for anti-angiogenic strategies.
Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM and Noel A
J Cell Biol, 152(4): 777-784, 2001
|
Membrane-Type 4-Matrix Metalloproteinase promotes breast cancer growth and metastase.
Chabottaux V, Sounni NE, English WR, Van den Brûle F, Gilles C, Munaut C, Maquoi E, Lopez-Otin C, Murphy G, Foidart JM and Noel A
Cancer Res, 66(10): 5165-72, 2006
|
Earlier onset of tumoural angiogenesis in matrix metalloproteinase-19 deficient mice.
Jost M, Folgueras AR, Frerart F, Pendas AM, Blacher S, Houard X, Berndt S, Cataldo D, Alvarez J, Melen-Lamalle L, Foidart .JM, Lopez-Otin C and Noel A
Cancer Res, 66(10): 5234-41, 2006
|
Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.
Jost M, Maillard C, Lecomte J, Lambert V, Tjwa M, Blaise P, Alvarez Gonzalez ML, Bajou K, Blacher S, Motte P, Humblet C, Defresne MP, Thiry M, Frankenne F, Gothot A, Carmeliet P, Rakic JM, Foidart JM, Noël A
Am J Pathol, 171(4): 1369-80, 2007
|
Modeling lymphangiogenesis in a three-dimensional culture system.
Bruyère F, Melen-Lamalle L, Blacher S, Roland G, Thiry M, Moons L, Frankenne F, Carmeliet P, Alitalo K, Libert C, Sleeman JP, Foidart JM, Noël A.
Nat Methods, 5(5): 431-7, 2008
|
The lymphatic ring assay: a 3D-culture model of lymphangiogenesis.
Bruyère F., Melen-Lamalle L., Berndt S., Peulen O., Foidart J.M., Noel A.
Nat Protocols, DOI 10.1038/nprot.2008.86, 2008
|
|
|
